Vir Biotechnology Inc VIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
-
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
-
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
-
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development
-
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
-
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
-
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
Trading Information
- Previous Close Price
- $7.56
- Day Range
- $7.33–7.79
- 52-Week Range
- $7.12–13.09
- Bid/Ask
- $7.29 / $7.78
- Market Cap
- $1.05 Bil
- Volume/Avg
- 695,045 / 803,132
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 587
- Website
- https://www.vir.bio
Comparables
Valuation
|
Metric
|
VIR
|
UTHR
|
BPMC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 15.00 | — |
Price/Book Value | 0.73 | 2.75 | 17.90 |
Price/Sales | 18.00 | 6.63 | 15.69 |
Price/Cash Flow | — | 14.21 | — |
Price/Earnings
VIR
UTHR
BPMC
Financial Strength
|
Metric
|
VIR
|
UTHR
|
BPMC
|
|---|---|---|---|
Quick Ratio | 11.94 | 3.92 | 3.48 |
Current Ratio | 12.51 | 4.35 | 3.71 |
Interest Coverage | — | 22.67 | −8.43 |
Quick Ratio
VIR
UTHR
BPMC
Profitability
|
Metric
|
VIR
|
UTHR
|
BPMC
|
|---|---|---|---|
Return on Assets (Normalized) | −16.27% | 16.95% | −24.11% |
Return on Equity (Normalized) | −19.53% | 20.53% | −104.04% |
Return on Invested Capital (Normalized) | −22.82% | 16.62% | −41.57% |
Return on Assets
VIR
UTHR
BPMC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qgbbcbmrlf | Xcm | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kwqqsly | Flktsq | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fpwzjsrp | Thmyjw | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mfckpgzrl | Swmlvkd | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Xchpxgml | Hnt | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Chkqntq | Fphy | $28.3 Bil | |||
| Moderna Inc
MRNA
| Vqthltmq | Cdb | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pbyxtdfvs | Jcwkv | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pmdrtnms | Ssnmny | $13.3 Bil | |||
| Incyte Corp
INCY
| Zghxqcjg | Pfjfhj | $13.0 Bil |
United States